CDC37 and cancer: Indeed, treatment with anti-CDC37 antibodies impairs cancer cell migration and in vivo administration of an HSP90 blocking antibody, able to disrupt the HSP90-CDC37 complex, inhibits metastasis formation (Stellas et al., 2007, 2010; El Hamidieh et al., 2012).